文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

全面的泛癌分析确定PLAG1是肿瘤免疫微环境的关键调节因子和预后生物标志物。

Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor immune microenvironment and prognostic biomarker.

作者信息

Wu Ruicheng, Li Dengxiong, Zhang Shuxia, Wang Jie, Yu Qingxin, Feng Dechao, Han Ping

机构信息

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

Division of Surgery and Interventional Science, University College London, London, United Kingdom.

出版信息

Front Immunol. 2025 Apr 10;16:1572108. doi: 10.3389/fimmu.2025.1572108. eCollection 2025.

DOI:10.3389/fimmu.2025.1572108
PMID:40276502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12018345/
Abstract

BACKGROUND: The literature on the role of pleomorphic adenoma gene 1 (PLAG1) in malignant tumors is limited. This study aimed to perform pan-cancer analysis of PLAG1. METHODS: The expression of PLAG1 was analyzed by Human Protein Atlas (HPA). The differential expression and prognosis of PLAG1 were analyzed based on TCGA pan-cancer data. The relationship between PLAG1 expression and tumor heterogeneity, stemness and immune infiltration was investigated. The enrichment analysis and biological function of PLAG1 in bladder cancer were analyzed. RESULTS: The expression of PLAG1 was increased in a variety of tumors and significantly correlated with the prognosis of patients. Their expression levels were associated with key immune checkpoint genes (CD274, HAVCR2), immune infiltration and immune stimulation factors (CD48, CD27). In bladder cancer, functional enrichment analysis indicated that PLAG1 was involved in epidermal related processes and immune pathways. PLAG1 gene expression reduction can significantly inhibit the proliferation of bladder cancer cells. CONCLUSIONS: PLAG1 has the potential to be a prognostic marker and a potential therapeutic target for patients with malignant tumors.

摘要

背景：关于多形性腺瘤基因1（PLAG1）在恶性肿瘤中作用的文献有限。本研究旨在对PLAG1进行泛癌分析。 方法：通过人类蛋白质图谱（HPA）分析PLAG1的表达。基于TCGA泛癌数据，分析PLAG1的差异表达及预后情况。研究PLAG1表达与肿瘤异质性、干性和免疫浸润之间的关系。分析PLAG1在膀胱癌中的富集分析及生物学功能。 结果：PLAG1在多种肿瘤中表达增加，且与患者预后显著相关。其表达水平与关键免疫检查点基因（CD274、HAVCR2）、免疫浸润及免疫刺激因子（CD48、CD27）相关。在膀胱癌中，功能富集分析表明PLAG1参与表皮相关过程和免疫途径。PLAG1基因表达降低可显著抑制膀胱癌细胞增殖。 结论：PLAG1有潜力成为恶性肿瘤患者的预后标志物和潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/26590e37f164/fimmu-16-1572108-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/bebf68fad15d/fimmu-16-1572108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/6a9e0d80dabb/fimmu-16-1572108-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/ff513c871477/fimmu-16-1572108-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/dd106be015bf/fimmu-16-1572108-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/ddaf874204a9/fimmu-16-1572108-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/737610ce640e/fimmu-16-1572108-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/c965971cd90d/fimmu-16-1572108-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/d83205e9aeff/fimmu-16-1572108-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/9d001498e114/fimmu-16-1572108-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/26590e37f164/fimmu-16-1572108-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/bebf68fad15d/fimmu-16-1572108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/6a9e0d80dabb/fimmu-16-1572108-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/ff513c871477/fimmu-16-1572108-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/dd106be015bf/fimmu-16-1572108-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/ddaf874204a9/fimmu-16-1572108-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/737610ce640e/fimmu-16-1572108-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/c965971cd90d/fimmu-16-1572108-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/d83205e9aeff/fimmu-16-1572108-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/9d001498e114/fimmu-16-1572108-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1568/12018345/26590e37f164/fimmu-16-1572108-g010.jpg

相似文献

[1]
Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor immune microenvironment and prognostic biomarker.

Front Immunol. 2025-4-10

[2]
The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.

Technol Health Care. 2024

[3]
Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.

Front Immunol. 2024-12-16

[4]
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer.

Sci Rep. 2024-8-16

[5]
RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation.

Int Immunopharmacol. 2024-12-25

[6]
Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.

Biomed Res Int. 2021

[7]
ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer.

Front Immunol. 2025-3-31

[8]
Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer.

Cancer Genet. 2024-11

[9]
Elucidating the expression and role of cGAS in pan-cancer using integrated bioinformatics and experimental approaches.

BMC Cancer. 2025-1-2

[10]
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.

Front Immunol. 2021

本文引用的文献

[1]
Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046.

Mil Med Res. 2025-3-17

[2]
The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Research (Wash D C). 2025-3-5

[3]
Basic helix-loop-helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases.

Burns Trauma. 2025-1-18

[4]
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

J Hematol Oncol. 2025-1-13

[5]
SnoRNAs: The promising targets for anti-tumor therapy.

J Pharm Anal. 2024-11

[6]
Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial.

Radiol Med. 2024-12

[7]
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis.

Chin J Cancer Res. 2024-6-30

[8]
Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1.

Cell Prolif. 2024-11

[9]
Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform.

Imeta. 2022-7-8

[10]
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.

Chin J Cancer Res. 2024-4-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索